Drug intelligence / Profile preview

leishmania vaccine (animal)

Development stage: Preclinical
Lead developer: SET Technology
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

Leishmania vaccine (animal) is a DNA/RNA-based vaccine candidate being developed by SET Technology for the prevention and treatment of leishmaniasis in veterinary subjects. Utilizing SET Technology's nucleic acid delivery platform, the vaccine is designed to stimulate a robust immune response against Leishmania parasites. The program is currently in the preclinical stage of development and is part of the company's animal health pipeline.

Other names: Leishmania Vax

Beyond the preview

Go deeper on leishmania vaccine (animal).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on leishmania vaccine (animal).

Explore the full profile